Ser403

Site Information
KRRQrGVsCFRtPFG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 30976422

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	breast cancer ( 1 ) , breast ductal carcinoma ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , H2009 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , HCC1359 (pulmonary) ( 3 ) , HCC2279 (pulmonary) ( 3 ) , HCC4006 (pulmonary) ( 3 ) , HeLa (cervical) ( 4 ) , K562 (erythroid) ( 2 ) , NCI-H1395 (pulmonary) ( 3 ) , NCI-H2030 (pulmonary) ( 3 ) , NCI-H2172 (pulmonary) ( 3 )

Upstream Regulation
Treatments:	ischemia ( 1 )

References
1	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
2	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
3	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
4	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info